Stoke Therapeutics Inc

+0.03 (+0.41%)
7:47:10 PM EDT: $7.08 -0.28 (-3.80%)
Earnings Announcements

Stoke Therapeutics Reports Q3 Financial Results And Provides Business Updates

Published: 11/14/2022 13:17 GMT
Stoke Therapeutics Inc (STOK) - Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates.
Positive Interim Data From Ongoing Phase 1/2a Clinical Studies of Stk-001 in Children and Adolescents With Dravet Syndrome.
Single and Multiple Doses of Stk-001 Up to 45mg Were Well-tolerated.
Qtrly Loss per Share $0.66.
Cash, Cash Equivalents, Marketable Securities, and Restricted Cash, Anticipated to Fund Operations Into 2025.
Q3 Earnings per Share View $-0.68 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.82 Million
Adjusted EPS is expected to be -$0.71

Next Quarter Revenue Guidance is expected to be $5 Million
Next Quarter EPS Guidance is expected to be -$0.71

More details on our Analysts Page.